M. Kreuter (Heidelberg, Germany), E. Bendstrup (Vejle, Denmark)
Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials
U. Costabel (Essen, Germany)
|   |
Treatment with nintedanib in patients with pleuroparenchymal fibroelastosis
M. Nasser (Bron, France)
| |
Clinical application of the COPD assessment test (CAT) in patients with idiopathic pulmonary fibrosis
S. Burhan Shaker (Rødovre, Denmark)
| |
Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world
C. Sugimoto (Sakai, Osaka, Japan)
| |
Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice
K. Babu (Portsmouth, United Kingdom)
| |
Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real- world results from the EMPIRE registry.
M. Vasakova (Prague, Czech Republic)
| |
Collaborating with stakeholders to advance the National Patient Charter for Idiopathic Pulmonary Fibrosis in Ireland.
N. Cassidy (Dublin 5, Ireland)
| |
An epidemiological study on the effect of age, sex and comorbidities on the clinical course of idiopathic pulmonary fibrosis
A. Caminati (Milano, MI, Italy)
| |
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain.
C. Valenzuela (Alcobendas (Madrid), Spain)
| |
Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
C. Moor (Rotterdam, Netherlands)
| |
The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
Y. Matsumoto (Tokyo, Japan)
| |
Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience.
A. Tzouvelekis (Athens, Greece)
| |
Tobacco smoking and risk for idiopathic pulmonary fibrosis: a prospective cohort study in UK Biobank
V. Bellou (Ioannina, Greece)
| |
The programmed death of alveolar lymphocytes is elevated in idiopathic pulmonary fibrosis (IPF). The plausible explanation of well-known bronchoalveolar lavage cytological findings?
P. Kopinski (Bydgoszcz, Poland)
| |
Role of MUC1 in idiopathic pulmonary fibrosis: mechanistic insights
B. Ballester (Burjassot (Valencia), Spain)
| |
Concomitant medications and efficacy of nintedanib in patients with IPF
M. Kreuter (Heidelberg, Germany)
| |
FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF
L. Richeldi (Southampton, United Kingdom)
| |